TY - JOUR
T1 - Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease
AU - Roney, Celeste
AU - Kulkarni, Padmakar
AU - Arora, Veera
AU - Antich, Peter
AU - Bonte, Frederick
AU - Wu, Aimei
AU - Mallikarjuana, N. N.
AU - Manohar, Sanjeev
AU - Liang, Hsiang Fa
AU - Kulkarni, Anandrao R.
AU - Sung, Hsing Wen
AU - Sairam, Malladi
AU - Aminabhavi, Tejraj M.
N1 - Funding Information:
This work was supported by NIH F31 GM06638-03. The authors would like to thank Drs. Charles White and Dwight German for supply of brain tissue, and the UT Southwestern Medical Center Alzheimer's Disease Center (ADC) for support of this work. The authors would like to thank Dr. Michael Bennett for consultation. The investigations were conducted in conjunction with Cancer Imaging Program Pre-ICMC P20 CA086354. This report represents the research efforts under the triangular MoU between the University of Texas Southwestern Medical Center at Dallas, the University of Texas at Dallas and Center of Excellence in Polymer Science, Karnatak University, Dharwad, India.
PY - 2005/11/28
Y1 - 2005/11/28
N2 - Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the central nervous system (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood-brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. This review gives an account of the BBB and discusses the literature on biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications that can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications in neurological disorders, such as AD. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.
AB - Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the central nervous system (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood-brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. This review gives an account of the BBB and discusses the literature on biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications that can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications in neurological disorders, such as AD. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.
KW - Alzheimer's disease
KW - Blood-brain barrier
KW - Central nervous system
KW - Nanoparticles
KW - Targeted drug delivery
UR - http://www.scopus.com/inward/record.url?scp=27744599588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744599588&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2005.07.024
DO - 10.1016/j.jconrel.2005.07.024
M3 - Article
C2 - 16246446
AN - SCOPUS:27744599588
SN - 0168-3659
VL - 108
SP - 193
EP - 214
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 2-3
ER -